Sanofi-Aventis Loses Another Patent Dispute

BMI View: With the approaching patent cliff - a period starting in 2009, peaking in 2011 and continuing through to 2013, when almost all the leading blockbusters will lose patent protection - pharmaceutical firms with heavy reliance on revenue generated from sales of patented drugs will endure significant drops in revenue. BMI forecasts the US generic drug market to reach US$111.02bn in 2019, growing at a compound annual growth rate (CAGR) of 5.45%. In comparison, the patented drug market is forecast to reach US$255.2bn but grow at a significantly slower rate, with a CAGR of 1.36% over the same period.

To read the full article, please choose one of the following options: